The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

An influenza vaccine candidate from Moderna showed promising results in a late-stage trial, bringing the drug maker one step ...

Moderna today reported promising relative vaccine efficacy (rVE) findings from a phase 3 trial of its seasonal mRNA flu ...

The mRNA drug developer said it will begin discussing approval with the FDA, which has adopted stricter vaccine review ...

It's a shot in the arm for Cambridge, Massachusetts-based Moderna as it faces an evolving regulatory environment for vaccines ...

The long and winding journey of Moderna’s mRNA flu vaccine toward regulators has come one step closer with a phase 3 win over an approved competitor shot. Moderna said its own vaccine, dubbed ...

The Trump administration recently canceled $766 million in contracts with Moderna to develop and produce an mRNA vaccine against pandemic influenza viruses, including H5N1 avian flu. This is a tragic ...

mRNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older ...

The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

The FDA has updated labels on the top two COVID-19 vaccines to warn of a rare heart side effect, mostly seen in young men.

Moderna disclosed that a study of 56,000 volunteers older than 50 found that its new mRNA influenza vaccine was 27% more effective than an existing influenza shot. That would mean that it is more ...

As a new variant that causes 'razor blade throat' spreads, the FDA updates vaccine warnings to include information on heart ...